Skip to main content

Clinical Trial Results

Search

Daniel P Judge and Dr. C. Michael Gibson Discuss: Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study

Disclosure: Sponsored by BridgeBio